Notice of Intent - Illumina Consumables and Reagents IDIQ
Overview
Buyer
Place of Performance
NAICS
PSC
Set Aside
Original Source
Timeline
Qualification Details
Fit reasons
- NAICS alignment with historical contract wins in similar service areas.
- Scope strongly matches core technical capabilities and delivery model.
Risks
- Past performance thresholds may require one additional teaming partner.
- Potential clarification needed on staffing minimums before bid/no-bid.
Next steps
Validate eligibility requirements, assign capture owner, and schedule partner outreach to confirm teaming strategy before submission planning.
Quick Summary
The Federal Bureau of Investigation (FBI) has issued a Notice of Intent to award a sole-source, Firm-Fixed-Price (FFP), Indefinite Delivery Indefinite Quantity (IDIQ) contract to Illumina, Inc. for Illumina reagents and consumables. This procurement is critical for the FBI's Laboratory Division to support Investigative Genetic Genealogy (IGG) investigations and DNA sequencing for information-investigation-intelligence (i3) casework. While this is not a request for competitive quotations, responsible sources may submit a capability statement and proposal/quotation for consideration. Responses are due by April 2, 2026, at 9:00 AM EST.
Scope of Work
The requirement is for Illumina-manufactured reagents and consumables necessary for the preparation of DNA sequencing and the operation of existing Illumina sequencing instruments (NextSeq 2000 and MiSeq i100 Plus). These items will support:
- Developing single-nucleotide polymorphism (SNP) profiles for IGG investigations.
- DNA sequencing for i3 casework.
Contract & Timeline
- Type: Sole-Source, Firm-Fixed-Price (FFP), Indefinite Delivery Indefinite Quantity (IDIQ)
- Contractor: Illumina, Inc.
- Duration: One base year with four option periods.
- Set-Aside: None (Sole Source Justification)
- Response Due: April 2, 2026, 9:00 AM EST
- Published: March 18, 2026
Evaluation
This notice is a sole-source justification, not a solicitation for proposals. Any submitted capability statements or proposals will be considered solely to determine if competition would be advantageous to the Government. A determination not to compete this requirement remains at the Government's discretion. Responses must include the firm's Unique Entity ID (UEI) number and Business Size.
Additional Notes
Illumina's sequencing instruments are proprietary, and their reagents and consumables are uniquely formulated and calibrated to their chemistry and Sequencing by Synthesis (SBS) technology. Illumina holds exclusive intellectual property rights, and there are no third-party manufacturers of equivalent products. The FBI previously procured two Illumina sequencing instruments in September 2025, and IGG is a priority for the Laboratory Division in FY2026.